prikaz prve stranice dokumenta Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
  Download
PDF 808.64 KB
Scientific paper - Original scientific paper
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
Cancers, 14 (2022), 22; 5530. https://doi.org/10.3390/cancers14225530
Cattaneo, Chiara; Salmanton-García, Jon; Marchesi, Francesco; El-Ashwah, Shaimaa; Itri, Federico; Weinbergerová, Barbora; Gomes Da Silva, Maria; Dargenio, Michelina; Dávila-Valls, Julio; Martín-Pérez, Sonia; Farina, Francesca; Van Doesum, Jaap; Valković, Toni; Besson, Caroline; Poulsen, Christian Bjørn; López-García, Alberto; Žák, Pavel; Schönlein, Martin; Piukovics, Klára; Jakšić, Ozren; Cabirta, Alba; Ali, Natasha; Sili, Uluhan; Fracchiolla, Nicola; Dragonetti, Giulia; Adžić-Vukičević, Tatjana; Marchetti, Monia; Machado, Marina; Glenthøj, Andreas; Finizio, Olimpia; Demirkan, Fatih; Blennow, Ola; Tisi, Maria Chiara; Omrani, Ali S.; Navrátil, Milan; Ráčil, Zdeněk; Novák, Jan; Magliano, Gabriele; Jiménez, Moraima; Garcia-Vidal, Carolina; Erben, Nurettin; Del Principe, Maria Ilaria; Buquicchio, Caterina; Bergantim, Rui; Batinić, Josip; Al-Khabori, Murtadha; Verga, Luisa; Szotkowski, Tomáš; Samarkos, Michail; Ormazabal-Vélez, Irati; Meers, Stef; Maertens, Johan; Pinczés, László Imre; Hoenigl, Martin; Drgoňa, Ľuboš; Cuccaro, Annarosa; Bilgin, Yavuz M.; Aujayeb, Avinash; Rahimli, Laman; Gräfe, Stefanie; Sciumè, Mariarita; Mladenović, Miloš; Çolak, Gökçe Melis; Sacchi, Maria Vittoria; Nordlander, Anna; Berg Venemyr, Caroline; Hanáková, Michaela; García-Poutón, Nicole; Emarah, Ziad; Zambrotta, Giovanni Paolo Maria; Nunes Rodrigues, Raquel; Cordoba, Raul; Méndez, Gustavo-Adolfo; Biernat, Monika M.; Cornely, Oliver A.; Pagano, Livio More authors...

Citations:
,

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Cattaneo, C., Salmanton García, J., Marchesi, F., El Ashwah, S., Itri, F., Weinbergerová, B. ... Pagano, L. (2022). Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. Cancers, 14. (22). doi: 10.3390/cancers14225530

Cattaneo, Chiara, et al. "Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey." Cancers, vol. 14, no. 22, 2022. https://doi.org/10.3390/cancers14225530

Cattaneo, Chiara, Jon Salmanton García, Francesco Marchesi, Shaimaa El Ashwah, Federico Itri, Barbora Weinbergerová, Maria Gomes Da Silva, et al. "Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey." Cancers 14, no. 22 (2022). https://doi.org/10.3390/cancers14225530

Cattaneo, C., et al. (2022) 'Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey', Cancers, 14(22). doi: 10.3390/cancers14225530

Cattaneo C, Salmanton García J, Marchesi F, El Ashwah S, Itri F, Weinbergerová B, and sur.. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. Cancers [Internet]. 2022 November 10 [cited 2025 March 14];14(22). doi: 10.3390/cancers14225530

C. Cattaneo, et al., "Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey", Cancers, vol. 14, no. 22, November 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:096700. [Accessed: 14 March 2025]

Metadata
Title (english)Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
AuthorChiara Cattaneo
AuthorJon Salmanton-García
AuthorFrancesco Marchesi
AuthorShaimaa El-Ashwah
AuthorFederico Itri
AuthorBarbora Weinbergerová
AuthorMaria Gomes Da Silva
AuthorMichelina Dargenio
AuthorJulio Dávila-Valls
AuthorSonia Martín-Pérez
AuthorFrancesca Farina
AuthorJaap Van Doesum
AuthorToni Valković
AuthorCaroline Besson
AuthorChristian Bjørn Poulsen
AuthorAlberto López-García
AuthorPavel Žák
AuthorMartin Schönlein
AuthorKlára Piukovics
AuthorOzren Jakšić
AuthorAlba Cabirta
AuthorNatasha Ali
AuthorUluhan Sili
AuthorNicola Fracchiolla
AuthorGiulia Dragonetti
AuthorTatjana Adžić-Vukičević
AuthorMonia Marchetti
AuthorMarina Machado
AuthorAndreas Glenthøj
AuthorOlimpia Finizio
AuthorFatih Demirkan
AuthorOla Blennow
AuthorMaria Chiara Tisi
AuthorAli S. Omrani
AuthorMilan Navrátil
AuthorZdeněk Ráčil
AuthorJan Novák
AuthorGabriele Magliano
AuthorMoraima Jiménez
AuthorCarolina Garcia-Vidal
AuthorNurettin Erben
AuthorMaria Ilaria Del Principe
AuthorCaterina Buquicchio
AuthorRui Bergantim
AuthorJosip Batinić
AuthorMurtadha Al-Khabori
AuthorLuisa Verga
AuthorTomáš Szotkowski
AuthorMichail Samarkos
AuthorIrati Ormazabal-Vélez
AuthorStef Meers
AuthorJohan Maertens
AuthorLászló Imre Pinczés
AuthorMartin Hoenigl
AuthorĽuboš Drgoňa
AuthorAnnarosa Cuccaro
AuthorYavuz M. Bilgin
AuthorAvinash Aujayeb
AuthorLaman Rahimli
AuthorStefanie Gräfe
AuthorMariarita Sciumè
AuthorMiloš Mladenović
AuthorGökçe Melis Çolak
AuthorMaria Vittoria Sacchi
AuthorAnna Nordlander
AuthorCaroline Berg Venemyr
AuthorMichaela Hanáková
AuthorNicole García-Poutón
AuthorZiad Emarah
AuthorGiovanni Paolo Maria Zambrotta
AuthorRaquel Nunes Rodrigues
AuthorRaul Cordoba
AuthorGustavo-Adolfo Méndez
AuthorMonika M. Biernat
AuthorOliver A. Cornely
AuthorLivio Pagano
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%)... More patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy. Less
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCancers
Numberingvol. 14, no. 22, 5530
e-ISSN2072-6694
DOIhttps://doi.org/10.3390/cancers14225530
URN:NBNurn:nbn:hr:105:096700
Publication2022-11-10
Document URLhttps://www.mdpi.com/2072-6694/14/22/5530
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-06-13 11:27:12
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.